Vaccination with a recombinant Vα domain of a TCR prevents the development of collagen-induced arthritis

Rosloniec, E. F., Brand, D. D., Whittington, K. B., Stuart, J. M., Ciubotaru, M. and Ward, E. S. (1995) Vaccination with a recombinant Vα domain of a TCR prevents the development of collagen-induced arthritis. Journal of Immunology, 155 (9), 4504-4511.

Abstract

A recombinant TCR domain, derived from a T cell hybridoma that recognizes an immunodominant type II collagen epitope, was used to vaccinate against collagen-induced arthritis in DBA/1 (H-2(q)) mice. The recombinant TCR domain comprises VA11.1-JA17 gene segments and is representative of the Vα domains expressed by oligoclonal T cells in this disease model. Vaccination of mice 28 days before type II collagen (CII) immunization with this Vα11.1 domain resulted in a significantly decreased incidence of arthritis in DBA/1 mice, in contrast to vaccination with a Vα4-Jα40 domain derived from an encephalitogenic T cell hybridoma specific for MBP. Disease blockade is accompanied by a reduction in T and B cell responses to both the immunogen bovine CII and the autoantigen murine CII. Vα4 and Vα11.1 domains were found to be highly immunogenic in DBA/1 mice, inducing both T cell proliferation and the production of Vα specific Abs, indicating that the vaccination effect of Vα11.1 is specific. This is the first report of Vα- directed immunotherapy in an autoimmune disease model and demonstrates the potential use of recombinant TCR vaccines in the treatment of autoimmune diseases that involve oligoclonal autoreactive T cells.

This record has no associated files available for download.

Contributors

Author: E. S. Ward

Download statistics